CA2203396A1 - A storage stable water solution for infusion containing a thrombin inhibitor - Google Patents
A storage stable water solution for infusion containing a thrombin inhibitorInfo
- Publication number
- CA2203396A1 CA2203396A1 CA002203396A CA2203396A CA2203396A1 CA 2203396 A1 CA2203396 A1 CA 2203396A1 CA 002203396 A CA002203396 A CA 002203396A CA 2203396 A CA2203396 A CA 2203396A CA 2203396 A1 CA2203396 A1 CA 2203396A1
- Authority
- CA
- Canada
- Prior art keywords
- hooc
- pic
- nag
- cha
- solution according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
- C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
Abstract
This invention relates to a storage stable concentrated water-solution for infusion having a pH in the range from 1.0 to 2.5 and containing an active thrombin inhibitor having the formula: HOOC-CH2-Y, wherein Y is (R)-Cha-Pic-Nag or (R)-Cgl-Aze-Pab, as a salt or as a free base thereof, a process for their preparation and to a method for treatment of a patient in need of said formulation.
Description
WO 96/14084 P~ ih55~'~,1228 A storage stable water solution for infusion con~ainin~ a thrombin inhibitor Field of the invention The present invention relates to a new improved storage stable intravenous formulation for infusion of thrombin inhibitors, especially of the pepffdic thrombin inhibitors HOOC~H2-(R)Cha-Pic-Nag and HOOC~H2-(R)Cgl -Aze-Pab, respectively, to a process for the preparation of said formulation and to a10 method for treatment by a~minictration of said formulaffons.
Background of the invention Thrombin inhibitors are expected to be effective drugs in a number of diseases 15 characterised by hypercoagulation. Their therapeutic use will be facilitated if stable formulations are available, i.e. formulations having a long shelf-life when stored at room-temperature.
In WO 93/111528, Example P1, a water solution for parenteral administration is 20 disclosed, said formulation is an acetate buffer-solution of HOOC-CH2-(R)Cha-Pic-Nag x 2HBr for parenteral use of pH 3-7, which is within the physiologicallyacceptable pH range suitable for injections directly into the human body. This solution also includes additives such as sodium chloride to get an isotonic solution.
The active compound HOOC-CH2-(R)~gl-Aze-Pab is disclosed in PCT/SE94/00535, filed 2 June 1994 and not yet published. Example P2 in this document describes a solution for parenteral administration, namely a water solution of an active compound and sodium chloride, which is adjusted with 30 NaOH to pH 3-9, preferably 5-7.
The stability of peptides is generally a problem in the pharmaceutical industry.Pharmaceutical formulations, especially with a low concentration of peptides, often loose activity during storage.
5 Each peptide is different with regard to pharrnacological properties. When preparing a pharmaceutical formulation of a specific pepffde, consideration can not only be taken to the pharmacological proper~ies of the peptide but also other aspects must be considered such as the industrial manufacture, easy and convenient storage and handling for the hospital staff and safety for the patient.
10 The results of these aspects are not predictable when testing different formulations and each peptide often has a unique solution regarding stability.
It is well known that peptides generally are more susceptible to degradation in an acidic or basic environment than in a neutral solution. However, unexpectedly it15 has been found that for the peptidic thrombin inhibitors HOOC-CH2-(R)-Cha-Pic-Nag and HOOC-CH2-(R)Cgl-Aze-Pab their storage stability is improved in acidic aqueous solutions.
Disclosure of the invention The scope of the present invention is a storage stable concentrated, water solution for intraveneous infusion of an active thrombin inhibitor having the formula wherein Y is (R)-Cha-Pic-Nag or (R)-Cgl-Aze-Pab and having a pH in the range 25 from 1.0 to 2.5, which solution does not require special storage conditions but can be stored at room temperature, i.e. between 15-30C, preferably between 18-28C,tentatively 25C.
Thus, the stable water solution of the present invention, which is a concentrated 30 water solution of a thrombin inhibitor, is adjusted with a physiologically acceptable organic or inorganic acid, preferably an inorganic mineral acid such as hydrochloric acid, hydrobromic acid etc., for obtaining the desired pH. The hydro chloric acid is most particularly yref~led. The forrnlllation is a straight forward one without any stabilising additives.
5 In an acidic solution the solubility of the two different drugs, respectively,increases and a more concentrated solution can be produced, which means that small containers which are easy to handle can be used.
It is of importance that the pharmaceutical formulation is easy to handle and to10 dose. Therefore said formulation suitably should be provided in containers intended for parenteral use, such as plastic or glass containers, e.g. vials, ampoules or prefilled syringes, and be added to infusion bags or bottles i.e. the storage stable concentrated water solution must be diluted before the administration to the patients.
An additional improvement is that the solutions do not require additives such asbuffer salts, isotonic salts or co-solvents for stability reasons. However, the stable solution may also contain preservatives, i.e. in order to prevent microbiological growth. The solution is aimed to be added to a solution for intravenous infusion20 such as physiological saline or other electrolytes, glucose, mannitol, dextran etc. or a combination thereof, and parenterally administered.
The solution may be manufactured with the acffve pepffdic thrombin inhibitors HOOC-CH2-(R)-Cha-Pic-Nag and HOOC-CH2-(R)Cgl-Aze-Pab, respecffvely, as 25 commonly used salts or in their base form.
The solution of the present invention will be stable enough to permit room temperature storage for extended periods. A commercial product should ~refe, ably have an storage period of at least two years, at the end of which period 30 at least 95% of the active compound should remain, that is the total amount of degradation products should be less than 5%.
-The ~refel . ed concentrations of HOOC-CH2-(R)~ha-Pic-Nag may vary within broad ranges between 0.001-200 mg/ml, preferably 0.1-100 mg/ml, more particularly preferred 10-100 mg/ml. The preferred concentrations of HOOC-CH2-(R)Cgl-Aze-Pab may vary within broad ranges between 0.001-300 mg/ml, pre~e~ably 0.1-200 mg/ml, more particularly l,re~ d 1-100 mg/ml.
This invention also relates to a process for the prepartion of a storage stable water solution, which comprises dissolving in water the active thrombin inhibitors HOOC-CH2-(R)Cha-Pic-Nag or HOOC~H2-(R)Cgl-Aze Pab, respectively, adjusting the pH of the obtained solution from 1.0 to 2.5, preferably from 1.5 to 2.0, or to a specific desired value, e.g. 1.0, 1.5, 2.0, 2.5. Suitable volumes when using ampoules, vials or syringes are 0.1-100 ml, pler~lably 1-10 ml.
The two active thrombin inhibitors, HOOC-CH2-(R)Cha-Pic-Nag and HOOC-CH2-(R)Cgl-A~e-Pab, respectively, are both possible to dissolve in water at roomtemperature.
Examples Analytical methods used in the examples below Stabilitv assay A stability indicating method using reversed-phase liquid chromatography in an ion-pair mode and W-detection at 210 and 238 nm was developed for HOOC-CH2-(R)Cha-Pic-Nag and HOOC-CH2-(R)Cgl -Aze-Pab, respectively.
A standard solution of thrombin inhibitors, 0.018-0.022 mg/mL was prepared, in mobile phase. The sample solution was diluted to a concentration of about 0.02 mg/ml with mobile phase. The column was equilibrated with mobile phase until a stable baseline was obtained. The standard and sample were injected at suitable intervals. The retention time for the active thrombin inhibitors HOOC~H2-(R)Cha-Pic-Nag and HOOC-CH2-(R)Cgl -Aze-Pab are about 4 and 12 minutes for the methods, res~e.li~7ely.
pH
The pH of the solutions was measured potentiometrically without prior diluffon using a Radiometer PHM Reference pH meter with a glass electrode (GK2401C
electrode).
The following examples illustrate but do not limit in any way the invention.
Example 1 15 This example presents the results from a stability study at 25C of a prior known acetate buffer solution containing the hydrobromide salt of HOOC-CH2-(R)Cha-Pic-Nag in two different concentrations and having pH 5.0 at the beginning of the study.
( i ) HOOC~H2-(R~Cha-Pic-Nag x 2HBr buffer solution (0.04 mg/ml), pH 5 Composition:
HOOC-CH2-(R)Cha-Pic-Nag x 2HBr 0.04 mg Sodium hydroxide 1 M to pH 5 q.s.
Acetate buffer 0.05 M (incl. NaCI, 9 mg/ml) to 1 ml Stabilihy Time pHTemperatureDegradation (months) (o C) (area % of active compound) 0 5.0 25 3 5.0 25 0.73 6 - 25 1.41 14 5.4 25 5.80 ( ii ) Hooc-cHr(R)cha-pic-Na~ x 2HBr buffer solution (9 m~/ml), pH5 Composition:
HOOC-CH2-(R)Cha-Pic-Nag x 2HBr 9 mg Sodium hydroxide 1 M to pH 5 q.s.
Acetate buffer 0.05 M (incl. NaCl, 9mg/ml) to 1 ml Stability Time pHTemy~.dl~re Degradation (months) ( C) (area % of active compound) 0 5.0 25 6 5.2 25 1.70 14 5.3 25 3.68 Conclusion This storage study indicates that storage at room temperature, 25C, for 2 yearswill not be acceptable depending on the large amount of degradation of the active compound.
Example 2 This example presents the results from a stability study at 25C of HOOC~Hr (R)Cha-Pic-Nag as a free base in the same concentration as Example 1 (ii) above,10 and starting at a pH about 5. The purpose of this study was to compare the stability of HOOC~H2-(R)Cha-Pic-Nag as a free base and as a salt thereof.
HOOC-CH2-(R)Cha-Pic-Nag buffer solution (9 mg/ml), pH 5 Composition:
HOOC-CH2-(R)Cha-Pic-Nag as free base 9 mg Hydrochloric acid 1 M to pH 5 q.s.
Acetate buffer 0.05 M (incl. NaCI, 9mg/ml) to 1 ml Stability Time pH T~ tureDegradation (months) (o C) (area % of active compound) 0 4.9 25 3 5.0 25 0.85 6 5.1 25 1.70 5.3 25 4.31 4 PCTtSE95101228 Conclusion This study shows that there is no big difference in storage stability at room temperature, 25C, by using HOOC-CH2-(R)Cha-Pic-Nag as a salt or as a free base (cf. Example 1).
Example 3 This example presents the result from a stability study at 25C of buffer solutions of HOOC-CH2-(R)Cha-Pic-Nag at different pHs between 3 to 9.
10 ( i ) HOOC-CH2-(R)Cha-Pic-Nag buffer soluffons (9 mg/ml) at different pHs Composition:
HOOC~H2-(R)Cha-Pic-Nag as free base 9 mg Hydrochloric acid (1 M) to pH q.s.
Acetate buffer 0.05 M (incl. Naa, 9 mg/ml) to 1 ml Stability Time pHTemperature Degrada'don (months) (o C) (area % of active compound) 0 3.0 25 4.0 5.0 3 3.6 25 0.75 4.2 0.78 5.0 0.85 6 3.8 25 1.30 44 1.48 5.1 1.70 PCI~/SE95/01228 ii ) HOOC-CH2-(R)Cha-Pic-Nag x 2 HCI buffer solutions (1 mg/ml) at different pHs Composiffon:
5 HOOC-CH2-(R)Cha-Pic-Nag x 2HCI 1 mg Buffer solution* to 1 ml * (for pH 4, 5 and 6 acetate buffer, for pH 8 phosphate buffer, for pH 9 carbonate buffer) Stability Time pHTem~_,al~c Degrâda~don (months) (o C) (area % of active compound) 3 4 25 1.1 1.3 6 25 2.4 8 25 10.8 9 25 12.2 Conclusion 15 This study shows that the degradation of HOOC-CH2-(R)Cha-Pic-Nag decreases at lower pH, independently of base or salt form.
Example 4 20 This example presents the result from a stability study at 25C of HOOC-CH2-(R)Cha-Pic-Nag in two different concentrations at pH about 1.5, namely from 1.5 to 1.6.
HOOC-CH2-(R)Cha-Pic-Nag water solution (0.4 mg/ml), pH 1.5 Composition:
5 HOOC-CH2-(R)Cha-Pic-Nag as free base 0.4 mg Hydrochloric acid 1 M to pH 1.5q.s.
Water to 1 ml 10 Stability Time pHTe~e.dture Degradation (months) (o C) (area % of active co~ou~ld) 0 1.5 25 3 1.5 25 0.27 6 1.6 25 0.58 12 1.6 25 1.36 ( ii ) HOOC-CH2-(R)Cha-Pic-Nag water solution (66 mg/ml), pH 1.5 15 Composition:
HOOC-CH2-(R)Cha-Pic-Nag as free base 66 mg Hydrochloric acid 1 M to pH 1.5 . q.s.
Water to 1 ml W O96/14084 11 PCT~E95/01228 Stability Time pHTemperature De~adation (months) (o C) (area % of active compound) 0 1.6 25 3 1.6 25 0.31 6 1.6 25 0.65 12 1.8 25 1.40 Conclusion This study shows that the degradation of HOOC-CH2-(R)Cha-Pic-Nag decreases 5 at this low pH.
Example 5 This example presents the result from a stability study at 25C of HOOC-CH2-10 (R)Cha-Pic-Nag in two different concentrations at pH 2Ø The purpose with this study is to compare the degradaffon of different pH in the range from 1.0 to 2.5 by comparing (i) with Example 4 (i).
( i ) HOOC-CH2-(R)Cha-Pic-Nag water solution (0.4 mg/ml), pH 2 Composition:
HOOC-CH2-(R)Cha-Pic-Nag as free base 0.4 mg Hydrochloric acid (1 M) to pH 2 q.s.
Water to 1 ml Stability Time pHTemperature De~radation (months) (o C) (area % of active compound) 0 2.0 25 3 2.0 25 0.46 6 2.0 25 0.91 12 2.2 25 2.05 ( ii ) HOOC-CH2-(R)Cha-Pic-Nag water solution (26 mg/ml), pH 2 Composition:
HOOC-CHr(R)Cha-Pic-Nag as free base 26 mg Hydrochloric acid 1 M to pH 2 q.s.
Water to 1 ml 10 Stability Time pH T~ tureDegradation (months) (o C) (area % of active compound) 0 2.1 25 3 2.1 25 0.45 6 2.1 25 0.94 12 2.4 25 1.93 Conclusion This study shows that the degradation is decreased at this low pH.
Example 6 s This example presents the results from a stability study at 25C of HOOC-CH2-(R)-Cgl-Aze Pab as free base.
HOOC-CH2-(R)~gl-Aze-Pab buffer solution (0.04 mg/ml), pH 6 Composition:
HOOC~H~(R)~gl-Aze Pab as free base 0.04 mg Sodium hydroxide (1 M) to pH 6 q.s.
Acetate buffer (0.05 M) (incl. NaCI 9 mg/ml) to 1 ml Stability Time pHTemperature Degradation (months) (o C) (area % of acti~ e co~ .d) 0 5.9 25 1.07 5.9 25 1.30 3 6.0 25 1.50 6 6.0 25 2.10 Conclusion This storage study shows that extended storage periods at 25C for this pH 6 formulation gives substantial degradation.
5 Example 7 This example presents the result from a stability study at 25C of HOOC-CHr(R)-Cgl-Aze Pab as buffer-solution and as water-solution, respectively, at different pHs.
10 HOOC~H2-(R)-C~I-Aze-Pab buffer solutions (12.9 mg/ml) at different pHs Composition:
( i ) HOOC~H2-(R)~gl-Aæ Pab as a free base 12.9mg Hydrochloric acid 1 M to pH q.s.
Acetate buffer 0.05 M (incl. NaCI, 9 mg/ml) to 1 ml Stability Time pH T~dture Degradatdon (months) (o C) (area % active compound) 3.7 25 0.59 5.1 0.55 6.2 074 3 3.5 25 0.51 5.2 0.46 6.3 0.79 6 4.3 25 0.58 5.4 0.70 6.3 0.~8 ( ii ) HOOC-CH2-(R)-Cgl-Aze-Pab water solutions (12.9 m~/ml) at different pH
Composition:
HOOC~H2-(R)-Cgl-Aze-Pab as free base 12.9 mg Hydrochloric acid 1 M to pH q.s.
Water to 1 ml 10Stability Time pHTe~l,elntuK Degradation ~months) (o C) (area % of ac'dve cu.l.~ound) 0 3.5 25 0.48 5.4 0.56 6.2 0.70 3.5 25 0.52 5.4 0.69 6.2 0.66 3 3.5 25 0.61 5.4 0.72 6.2 1.00 Conclusion This study shows that the degradation of HOOC-CH2-(R)~gl-A~Pab decreases 15 at lower pH, with or without buffer systems.
-Example 8 This example presents the result from a stability study at 50C of HOOC~H2-(R)-Cgl-Aze-Pab as water-solution, at different pHs.
5 HOOC-CH2-(R)-Cgl-Aze-Pab water solutions (12.0 mg/ml) at different pHs Composiffon:
( i ) HOOC~H2-(R)~gl-Aze-Pab as a free base 12.0 mg Hydrochloric acid 1 M or NaOH 1 M to pH q.s.
Water to 1 ml Stability Time pHTe~.~ye~lureMajor degradation (weeks) (o C) product (area % active compound) 0 2 50 0.57 4 0.42 7 0.44 9 2.41 2 2 50 0.47 4 0.48 7 3.31 9 25.6 4 2 50 0.50 4 0.58 7 6.76 9 33.8 Conclusion This study shows that also at elevated temperature the degradation of HOOC-- CH2-(R)-Cgl-Aze-Pab decreases at lower pH.
Final conclusions The studies above show that at room temperature, 25C, the degradation of the active thrombin inhibitors HOOC-CH2-(R)Cha-Pic-Nag and HOOC-CH2-(R)-Cgl-Aze-Pab, respectivily, independently as a free base or as a salt and independently 10 of concentraffon of active compound, decreases at lower pH.
Furthermore, the studies show that water solutions of said thrombin inhibitors having a pH in the range from 1.0 to 2.5, are more storage stable at room temperatur for extended periods.
Background of the invention Thrombin inhibitors are expected to be effective drugs in a number of diseases 15 characterised by hypercoagulation. Their therapeutic use will be facilitated if stable formulations are available, i.e. formulations having a long shelf-life when stored at room-temperature.
In WO 93/111528, Example P1, a water solution for parenteral administration is 20 disclosed, said formulation is an acetate buffer-solution of HOOC-CH2-(R)Cha-Pic-Nag x 2HBr for parenteral use of pH 3-7, which is within the physiologicallyacceptable pH range suitable for injections directly into the human body. This solution also includes additives such as sodium chloride to get an isotonic solution.
The active compound HOOC-CH2-(R)~gl-Aze-Pab is disclosed in PCT/SE94/00535, filed 2 June 1994 and not yet published. Example P2 in this document describes a solution for parenteral administration, namely a water solution of an active compound and sodium chloride, which is adjusted with 30 NaOH to pH 3-9, preferably 5-7.
The stability of peptides is generally a problem in the pharmaceutical industry.Pharmaceutical formulations, especially with a low concentration of peptides, often loose activity during storage.
5 Each peptide is different with regard to pharrnacological properties. When preparing a pharmaceutical formulation of a specific pepffde, consideration can not only be taken to the pharmacological proper~ies of the peptide but also other aspects must be considered such as the industrial manufacture, easy and convenient storage and handling for the hospital staff and safety for the patient.
10 The results of these aspects are not predictable when testing different formulations and each peptide often has a unique solution regarding stability.
It is well known that peptides generally are more susceptible to degradation in an acidic or basic environment than in a neutral solution. However, unexpectedly it15 has been found that for the peptidic thrombin inhibitors HOOC-CH2-(R)-Cha-Pic-Nag and HOOC-CH2-(R)Cgl-Aze-Pab their storage stability is improved in acidic aqueous solutions.
Disclosure of the invention The scope of the present invention is a storage stable concentrated, water solution for intraveneous infusion of an active thrombin inhibitor having the formula wherein Y is (R)-Cha-Pic-Nag or (R)-Cgl-Aze-Pab and having a pH in the range 25 from 1.0 to 2.5, which solution does not require special storage conditions but can be stored at room temperature, i.e. between 15-30C, preferably between 18-28C,tentatively 25C.
Thus, the stable water solution of the present invention, which is a concentrated 30 water solution of a thrombin inhibitor, is adjusted with a physiologically acceptable organic or inorganic acid, preferably an inorganic mineral acid such as hydrochloric acid, hydrobromic acid etc., for obtaining the desired pH. The hydro chloric acid is most particularly yref~led. The forrnlllation is a straight forward one without any stabilising additives.
5 In an acidic solution the solubility of the two different drugs, respectively,increases and a more concentrated solution can be produced, which means that small containers which are easy to handle can be used.
It is of importance that the pharmaceutical formulation is easy to handle and to10 dose. Therefore said formulation suitably should be provided in containers intended for parenteral use, such as plastic or glass containers, e.g. vials, ampoules or prefilled syringes, and be added to infusion bags or bottles i.e. the storage stable concentrated water solution must be diluted before the administration to the patients.
An additional improvement is that the solutions do not require additives such asbuffer salts, isotonic salts or co-solvents for stability reasons. However, the stable solution may also contain preservatives, i.e. in order to prevent microbiological growth. The solution is aimed to be added to a solution for intravenous infusion20 such as physiological saline or other electrolytes, glucose, mannitol, dextran etc. or a combination thereof, and parenterally administered.
The solution may be manufactured with the acffve pepffdic thrombin inhibitors HOOC-CH2-(R)-Cha-Pic-Nag and HOOC-CH2-(R)Cgl-Aze-Pab, respecffvely, as 25 commonly used salts or in their base form.
The solution of the present invention will be stable enough to permit room temperature storage for extended periods. A commercial product should ~refe, ably have an storage period of at least two years, at the end of which period 30 at least 95% of the active compound should remain, that is the total amount of degradation products should be less than 5%.
-The ~refel . ed concentrations of HOOC-CH2-(R)~ha-Pic-Nag may vary within broad ranges between 0.001-200 mg/ml, preferably 0.1-100 mg/ml, more particularly preferred 10-100 mg/ml. The preferred concentrations of HOOC-CH2-(R)Cgl-Aze-Pab may vary within broad ranges between 0.001-300 mg/ml, pre~e~ably 0.1-200 mg/ml, more particularly l,re~ d 1-100 mg/ml.
This invention also relates to a process for the prepartion of a storage stable water solution, which comprises dissolving in water the active thrombin inhibitors HOOC-CH2-(R)Cha-Pic-Nag or HOOC~H2-(R)Cgl-Aze Pab, respectively, adjusting the pH of the obtained solution from 1.0 to 2.5, preferably from 1.5 to 2.0, or to a specific desired value, e.g. 1.0, 1.5, 2.0, 2.5. Suitable volumes when using ampoules, vials or syringes are 0.1-100 ml, pler~lably 1-10 ml.
The two active thrombin inhibitors, HOOC-CH2-(R)Cha-Pic-Nag and HOOC-CH2-(R)Cgl-A~e-Pab, respectively, are both possible to dissolve in water at roomtemperature.
Examples Analytical methods used in the examples below Stabilitv assay A stability indicating method using reversed-phase liquid chromatography in an ion-pair mode and W-detection at 210 and 238 nm was developed for HOOC-CH2-(R)Cha-Pic-Nag and HOOC-CH2-(R)Cgl -Aze-Pab, respectively.
A standard solution of thrombin inhibitors, 0.018-0.022 mg/mL was prepared, in mobile phase. The sample solution was diluted to a concentration of about 0.02 mg/ml with mobile phase. The column was equilibrated with mobile phase until a stable baseline was obtained. The standard and sample were injected at suitable intervals. The retention time for the active thrombin inhibitors HOOC~H2-(R)Cha-Pic-Nag and HOOC-CH2-(R)Cgl -Aze-Pab are about 4 and 12 minutes for the methods, res~e.li~7ely.
pH
The pH of the solutions was measured potentiometrically without prior diluffon using a Radiometer PHM Reference pH meter with a glass electrode (GK2401C
electrode).
The following examples illustrate but do not limit in any way the invention.
Example 1 15 This example presents the results from a stability study at 25C of a prior known acetate buffer solution containing the hydrobromide salt of HOOC-CH2-(R)Cha-Pic-Nag in two different concentrations and having pH 5.0 at the beginning of the study.
( i ) HOOC~H2-(R~Cha-Pic-Nag x 2HBr buffer solution (0.04 mg/ml), pH 5 Composition:
HOOC-CH2-(R)Cha-Pic-Nag x 2HBr 0.04 mg Sodium hydroxide 1 M to pH 5 q.s.
Acetate buffer 0.05 M (incl. NaCI, 9 mg/ml) to 1 ml Stabilihy Time pHTemperatureDegradation (months) (o C) (area % of active compound) 0 5.0 25 3 5.0 25 0.73 6 - 25 1.41 14 5.4 25 5.80 ( ii ) Hooc-cHr(R)cha-pic-Na~ x 2HBr buffer solution (9 m~/ml), pH5 Composition:
HOOC-CH2-(R)Cha-Pic-Nag x 2HBr 9 mg Sodium hydroxide 1 M to pH 5 q.s.
Acetate buffer 0.05 M (incl. NaCl, 9mg/ml) to 1 ml Stability Time pHTemy~.dl~re Degradation (months) ( C) (area % of active compound) 0 5.0 25 6 5.2 25 1.70 14 5.3 25 3.68 Conclusion This storage study indicates that storage at room temperature, 25C, for 2 yearswill not be acceptable depending on the large amount of degradation of the active compound.
Example 2 This example presents the results from a stability study at 25C of HOOC~Hr (R)Cha-Pic-Nag as a free base in the same concentration as Example 1 (ii) above,10 and starting at a pH about 5. The purpose of this study was to compare the stability of HOOC~H2-(R)Cha-Pic-Nag as a free base and as a salt thereof.
HOOC-CH2-(R)Cha-Pic-Nag buffer solution (9 mg/ml), pH 5 Composition:
HOOC-CH2-(R)Cha-Pic-Nag as free base 9 mg Hydrochloric acid 1 M to pH 5 q.s.
Acetate buffer 0.05 M (incl. NaCI, 9mg/ml) to 1 ml Stability Time pH T~ tureDegradation (months) (o C) (area % of active compound) 0 4.9 25 3 5.0 25 0.85 6 5.1 25 1.70 5.3 25 4.31 4 PCTtSE95101228 Conclusion This study shows that there is no big difference in storage stability at room temperature, 25C, by using HOOC-CH2-(R)Cha-Pic-Nag as a salt or as a free base (cf. Example 1).
Example 3 This example presents the result from a stability study at 25C of buffer solutions of HOOC-CH2-(R)Cha-Pic-Nag at different pHs between 3 to 9.
10 ( i ) HOOC-CH2-(R)Cha-Pic-Nag buffer soluffons (9 mg/ml) at different pHs Composition:
HOOC~H2-(R)Cha-Pic-Nag as free base 9 mg Hydrochloric acid (1 M) to pH q.s.
Acetate buffer 0.05 M (incl. Naa, 9 mg/ml) to 1 ml Stability Time pHTemperature Degrada'don (months) (o C) (area % of active compound) 0 3.0 25 4.0 5.0 3 3.6 25 0.75 4.2 0.78 5.0 0.85 6 3.8 25 1.30 44 1.48 5.1 1.70 PCI~/SE95/01228 ii ) HOOC-CH2-(R)Cha-Pic-Nag x 2 HCI buffer solutions (1 mg/ml) at different pHs Composiffon:
5 HOOC-CH2-(R)Cha-Pic-Nag x 2HCI 1 mg Buffer solution* to 1 ml * (for pH 4, 5 and 6 acetate buffer, for pH 8 phosphate buffer, for pH 9 carbonate buffer) Stability Time pHTem~_,al~c Degrâda~don (months) (o C) (area % of active compound) 3 4 25 1.1 1.3 6 25 2.4 8 25 10.8 9 25 12.2 Conclusion 15 This study shows that the degradation of HOOC-CH2-(R)Cha-Pic-Nag decreases at lower pH, independently of base or salt form.
Example 4 20 This example presents the result from a stability study at 25C of HOOC-CH2-(R)Cha-Pic-Nag in two different concentrations at pH about 1.5, namely from 1.5 to 1.6.
HOOC-CH2-(R)Cha-Pic-Nag water solution (0.4 mg/ml), pH 1.5 Composition:
5 HOOC-CH2-(R)Cha-Pic-Nag as free base 0.4 mg Hydrochloric acid 1 M to pH 1.5q.s.
Water to 1 ml 10 Stability Time pHTe~e.dture Degradation (months) (o C) (area % of active co~ou~ld) 0 1.5 25 3 1.5 25 0.27 6 1.6 25 0.58 12 1.6 25 1.36 ( ii ) HOOC-CH2-(R)Cha-Pic-Nag water solution (66 mg/ml), pH 1.5 15 Composition:
HOOC-CH2-(R)Cha-Pic-Nag as free base 66 mg Hydrochloric acid 1 M to pH 1.5 . q.s.
Water to 1 ml W O96/14084 11 PCT~E95/01228 Stability Time pHTemperature De~adation (months) (o C) (area % of active compound) 0 1.6 25 3 1.6 25 0.31 6 1.6 25 0.65 12 1.8 25 1.40 Conclusion This study shows that the degradation of HOOC-CH2-(R)Cha-Pic-Nag decreases 5 at this low pH.
Example 5 This example presents the result from a stability study at 25C of HOOC-CH2-10 (R)Cha-Pic-Nag in two different concentrations at pH 2Ø The purpose with this study is to compare the degradaffon of different pH in the range from 1.0 to 2.5 by comparing (i) with Example 4 (i).
( i ) HOOC-CH2-(R)Cha-Pic-Nag water solution (0.4 mg/ml), pH 2 Composition:
HOOC-CH2-(R)Cha-Pic-Nag as free base 0.4 mg Hydrochloric acid (1 M) to pH 2 q.s.
Water to 1 ml Stability Time pHTemperature De~radation (months) (o C) (area % of active compound) 0 2.0 25 3 2.0 25 0.46 6 2.0 25 0.91 12 2.2 25 2.05 ( ii ) HOOC-CH2-(R)Cha-Pic-Nag water solution (26 mg/ml), pH 2 Composition:
HOOC-CHr(R)Cha-Pic-Nag as free base 26 mg Hydrochloric acid 1 M to pH 2 q.s.
Water to 1 ml 10 Stability Time pH T~ tureDegradation (months) (o C) (area % of active compound) 0 2.1 25 3 2.1 25 0.45 6 2.1 25 0.94 12 2.4 25 1.93 Conclusion This study shows that the degradation is decreased at this low pH.
Example 6 s This example presents the results from a stability study at 25C of HOOC-CH2-(R)-Cgl-Aze Pab as free base.
HOOC-CH2-(R)~gl-Aze-Pab buffer solution (0.04 mg/ml), pH 6 Composition:
HOOC~H~(R)~gl-Aze Pab as free base 0.04 mg Sodium hydroxide (1 M) to pH 6 q.s.
Acetate buffer (0.05 M) (incl. NaCI 9 mg/ml) to 1 ml Stability Time pHTemperature Degradation (months) (o C) (area % of acti~ e co~ .d) 0 5.9 25 1.07 5.9 25 1.30 3 6.0 25 1.50 6 6.0 25 2.10 Conclusion This storage study shows that extended storage periods at 25C for this pH 6 formulation gives substantial degradation.
5 Example 7 This example presents the result from a stability study at 25C of HOOC-CHr(R)-Cgl-Aze Pab as buffer-solution and as water-solution, respectively, at different pHs.
10 HOOC~H2-(R)-C~I-Aze-Pab buffer solutions (12.9 mg/ml) at different pHs Composition:
( i ) HOOC~H2-(R)~gl-Aæ Pab as a free base 12.9mg Hydrochloric acid 1 M to pH q.s.
Acetate buffer 0.05 M (incl. NaCI, 9 mg/ml) to 1 ml Stability Time pH T~dture Degradatdon (months) (o C) (area % active compound) 3.7 25 0.59 5.1 0.55 6.2 074 3 3.5 25 0.51 5.2 0.46 6.3 0.79 6 4.3 25 0.58 5.4 0.70 6.3 0.~8 ( ii ) HOOC-CH2-(R)-Cgl-Aze-Pab water solutions (12.9 m~/ml) at different pH
Composition:
HOOC~H2-(R)-Cgl-Aze-Pab as free base 12.9 mg Hydrochloric acid 1 M to pH q.s.
Water to 1 ml 10Stability Time pHTe~l,elntuK Degradation ~months) (o C) (area % of ac'dve cu.l.~ound) 0 3.5 25 0.48 5.4 0.56 6.2 0.70 3.5 25 0.52 5.4 0.69 6.2 0.66 3 3.5 25 0.61 5.4 0.72 6.2 1.00 Conclusion This study shows that the degradation of HOOC-CH2-(R)~gl-A~Pab decreases 15 at lower pH, with or without buffer systems.
-Example 8 This example presents the result from a stability study at 50C of HOOC~H2-(R)-Cgl-Aze-Pab as water-solution, at different pHs.
5 HOOC-CH2-(R)-Cgl-Aze-Pab water solutions (12.0 mg/ml) at different pHs Composiffon:
( i ) HOOC~H2-(R)~gl-Aze-Pab as a free base 12.0 mg Hydrochloric acid 1 M or NaOH 1 M to pH q.s.
Water to 1 ml Stability Time pHTe~.~ye~lureMajor degradation (weeks) (o C) product (area % active compound) 0 2 50 0.57 4 0.42 7 0.44 9 2.41 2 2 50 0.47 4 0.48 7 3.31 9 25.6 4 2 50 0.50 4 0.58 7 6.76 9 33.8 Conclusion This study shows that also at elevated temperature the degradation of HOOC-- CH2-(R)-Cgl-Aze-Pab decreases at lower pH.
Final conclusions The studies above show that at room temperature, 25C, the degradation of the active thrombin inhibitors HOOC-CH2-(R)Cha-Pic-Nag and HOOC-CH2-(R)-Cgl-Aze-Pab, respectivily, independently as a free base or as a salt and independently 10 of concentraffon of active compound, decreases at lower pH.
Furthermore, the studies show that water solutions of said thrombin inhibitors having a pH in the range from 1.0 to 2.5, are more storage stable at room temperatur for extended periods.
Claims (15)
1. A storage stable concentrated water solution for infusion having a pH in the range from 1.0 to 2.5 and containing an active thrombin inhibitor having the formula wherein Y is (R)-Cha-Pic-Nag or (R)-Cgl-Aze-Pab, as a salt or as a free base thereof.
2. The solution according to claim 1 wherein the thrombin inhibitor is HOOC-CH2-(R)-Cha-Pic-Nag as the free base.
3. The solution according to claim 1 the thrombin inhibitor is HOOC-CH2-(R)-Cgl-Aze-Pab as the free base.
4. The solution according to claim 1 wherein the pH is from 1.5 to 2Ø
5. The solution according to any one of the claims 1, 2 or 4 wherein the concentration of active thrombin inhibitor is between 0.001 to 200 mg/ml.
6. The solution according to any one of the claims 1, 3 or 4 wherein the concentration of active thrombin inhibitor is between 0.001 to 300 mg/ml.
7. The solution according to any one of the claims 1, 2, 4 or 5 consisting of the active compound HOOC-CH2-(R)-Cha-Pic-Nag, water and an inorganic mineral acid.
8. The solution according to any of the claims 1, 3, 4 or 6 consisting of the active compound HOOC-CH2-Cgl-Aze-Pab, water and an inorganic mineral acid.
9. The solution according to claims 7 or 8, wherein the inorganic mineral acid is hydrochloric acid.
10. The solution according to any one of claims 1-9, in which after storage at room temperature for at least two years at least 95% of the active compound remains.
11. A process for preparing a storage stabil concentrated water solution according to any one of the preceeding claims 1-10 which comprises dissolving the active thrombin inhibitor in water, adjusting of the solution pH to the range 1.0 to 2.5.
12. A process according to claim 11, wherein hydrochloric acid is used to adjustpH.
13. Use of a storage stable concentrated water solution according to any one of claims 1-10 for inhibition of thrombin.
14. A method for the treatment of a patient in need of a thrombin inhibitor by administration intravenously by infusion the storage stable concentrated water-solution according to any one of claims 1-10.
15. A method for stabilizing an active thrombin inhibitor having the formula wherein Y is (R)-Cha-Pic-Nag or (R)-Cgl-Aze-Pab, as a salt or as a free base thereof, comprising dissolving said thrombin inhibitor in water and adjusting the obtained solution with a physiologically acceptable organic or inorganic acid for obtaining a pH from 1.0 to 2.5.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9403831A SE504185C2 (en) | 1994-11-08 | 1994-11-08 | Storage-stable aqueous solution for infusion of thrombin inhibitors |
| SE9403831-2 | 1994-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2203396A1 true CA2203396A1 (en) | 1996-05-17 |
Family
ID=20395892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002203396A Abandoned CA2203396A1 (en) | 1994-11-08 | 1995-10-19 | A storage stable water solution for infusion containing a thrombin inhibitor |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US5830865A (en) |
| EP (1) | EP0789585B1 (en) |
| JP (1) | JPH10508598A (en) |
| KR (1) | KR100416677B1 (en) |
| CN (1) | CN1090508C (en) |
| AT (1) | ATE205399T1 (en) |
| AU (1) | AU695719B2 (en) |
| BR (1) | BR9509634A (en) |
| CA (1) | CA2203396A1 (en) |
| CZ (1) | CZ287256B6 (en) |
| DE (1) | DE69522702T2 (en) |
| DK (1) | DK0789585T3 (en) |
| EE (1) | EE9700218A (en) |
| ES (1) | ES2163528T3 (en) |
| FI (1) | FI971949A (en) |
| HU (1) | HU217073B (en) |
| IL (1) | IL115879A (en) |
| IS (1) | IS4468A (en) |
| MX (1) | MX9703339A (en) |
| MY (1) | MY112593A (en) |
| NO (1) | NO322048B1 (en) |
| NZ (1) | NZ295492A (en) |
| PL (1) | PL320342A1 (en) |
| PT (1) | PT789585E (en) |
| RU (1) | RU2164803C2 (en) |
| SE (1) | SE504185C2 (en) |
| SK (1) | SK53597A3 (en) |
| TR (1) | TR199501391A2 (en) |
| TW (1) | TW407057B (en) |
| WO (1) | WO1996014084A1 (en) |
| ZA (1) | ZA959377B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9301916D0 (en) * | 1993-06-03 | 1993-06-03 | Ab Astra | NEW PEPTIDES DERIVATIVES |
| US6984627B1 (en) * | 1993-06-03 | 2006-01-10 | Astrazeneca Ab | Peptide derivatives |
| TWI238827B (en) | 1995-12-21 | 2005-09-01 | Astrazeneca Ab | Prodrugs of thrombin inhibitors |
| SE9802974D0 (en) * | 1998-09-03 | 1998-09-03 | Astra Ab | New crystalline forms |
| US6462021B1 (en) | 2000-11-06 | 2002-10-08 | Astrazeneca Ab | Use of low molecular weight thrombin inhibitor |
| SI1569912T1 (en) | 2002-12-03 | 2015-09-30 | Pharmacyclics Llc | 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors |
| US7345093B2 (en) * | 2004-04-27 | 2008-03-18 | Formatech, Inc. | Methods of enhancing solubility of compounds |
| US20110070294A1 (en) * | 2009-09-23 | 2011-03-24 | Javeri Indu | Methods for the Administration of Drugs Using Liposomes |
| US10143652B2 (en) | 2009-09-23 | 2018-12-04 | Curirx Inc. | Methods for the preparation of liposomes |
| WO2011038068A1 (en) | 2009-09-23 | 2011-03-31 | Formatech, Inc. | Methods for the preparation of liposomes |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9103612D0 (en) * | 1991-12-04 | 1991-12-04 | Astra Ab | NEW PEPTIDE DERIVATIVES |
| US5466131A (en) * | 1994-03-22 | 1995-11-14 | Micropump Corporation | Multiple-chamber gear pump with hydraulically connected chambers |
-
1994
- 1994-11-08 SE SE9403831A patent/SE504185C2/en not_active IP Right Cessation
-
1995
- 1995-10-04 TW TW084110363A patent/TW407057B/en not_active IP Right Cessation
- 1995-10-19 HU HU9800400A patent/HU217073B/en not_active IP Right Cessation
- 1995-10-19 NZ NZ295492A patent/NZ295492A/en unknown
- 1995-10-19 PL PL95320342A patent/PL320342A1/en unknown
- 1995-10-19 WO PCT/SE1995/001228 patent/WO1996014084A1/en active IP Right Grant
- 1995-10-19 PT PT95938085T patent/PT789585E/en unknown
- 1995-10-19 US US08/557,189 patent/US5830865A/en not_active Expired - Fee Related
- 1995-10-19 CA CA002203396A patent/CA2203396A1/en not_active Abandoned
- 1995-10-19 MX MX9703339A patent/MX9703339A/en not_active IP Right Cessation
- 1995-10-19 CN CN95196108A patent/CN1090508C/en not_active Expired - Fee Related
- 1995-10-19 DE DE69522702T patent/DE69522702T2/en not_active Expired - Fee Related
- 1995-10-19 RU RU97108965/14A patent/RU2164803C2/en active
- 1995-10-19 EP EP95938085A patent/EP0789585B1/en not_active Expired - Lifetime
- 1995-10-19 ES ES95938085T patent/ES2163528T3/en not_active Expired - Lifetime
- 1995-10-19 SK SK535-97A patent/SK53597A3/en unknown
- 1995-10-19 AU AU38846/95A patent/AU695719B2/en not_active Ceased
- 1995-10-19 EE EE9700218A patent/EE9700218A/en unknown
- 1995-10-19 DK DK95938085T patent/DK0789585T3/en active
- 1995-10-19 CZ CZ19971294A patent/CZ287256B6/en not_active IP Right Cessation
- 1995-10-19 BR BR9509634A patent/BR9509634A/en active Search and Examination
- 1995-10-19 KR KR1019970703043A patent/KR100416677B1/en not_active IP Right Cessation
- 1995-10-19 AT AT95938085T patent/ATE205399T1/en not_active IP Right Cessation
- 1995-10-19 JP JP8515235A patent/JPH10508598A/en not_active Ceased
- 1995-10-26 MY MYPI95003226A patent/MY112593A/en unknown
- 1995-11-06 ZA ZA959377A patent/ZA959377B/en unknown
- 1995-11-06 IL IL11587995A patent/IL115879A/en not_active IP Right Cessation
- 1995-11-08 TR TR95/01391A patent/TR199501391A2/en unknown
-
1997
- 1997-04-21 IS IS4468A patent/IS4468A/en unknown
- 1997-05-05 NO NO19972065A patent/NO322048B1/en unknown
- 1997-05-07 FI FI971949A patent/FI971949A/en not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10406226B2 (en) | Method of manufacturing VEGF antagonist fusion proteins | |
| FI86254C (en) | FOERFARANDE FOER FRAMSTAELLNING AV INSULINPREPARAT. | |
| IE921124A1 (en) | Stabilized factor viii preparations | |
| KR102231957B1 (en) | Stable liquid formulation of etelcalcetide(amg 416) | |
| HU202761B (en) | Process for producing stabilized erythropoietin compositions | |
| US7803762B1 (en) | Ready-to-use bivalirudin compositions | |
| EP0652751A1 (en) | Injection and injection kit containing omeprazole and its analogs. | |
| JP2012056960A (en) | Preparation containing soluble thrombomodulin | |
| IE64080B1 (en) | Pharmaceutical for subcutaneous administration containing polypeptides | |
| CA2203396A1 (en) | A storage stable water solution for infusion containing a thrombin inhibitor | |
| KR20190071760A (en) | Pharmaceutical formulations and methods for their preparation | |
| EP1479393B1 (en) | Stabilized albumin preparations | |
| US5866591A (en) | Stable formulations of remifentanil | |
| CA1338699C (en) | Modified tpa-containing injection composition | |
| EP0419252B1 (en) | Thrombolytic composition containing tissue type plasminogen activator or derivative thereof | |
| WO2006096079A2 (en) | Pharmaceutical composition comprising a biosynthetic analog of human insulin, and its use in the treatment of diabetes mellitus. | |
| WO2023233277A1 (en) | Lyophilized pharmaceutical compositions of copper histidinate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |